William Rastetter has become non-executive chairman of Illumina’s board of directors, while current board chair John Stuelpnagel has been appointed to the new position of chief operating officer, Illumina announced last week. Rastetter will continue to serve as full-time executive chairman of Biogen Idec. He was the CEO of Biogen from 1986 to 2003, when it merged with Idec Pharamaceuticals. Stuelpnagel is a founding member of Illumina, and once served as its CEO and chief financial officer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.